IN2014MN01560A - - Google Patents

Info

Publication number
IN2014MN01560A
IN2014MN01560A IN1560MUN2014A IN2014MN01560A IN 2014MN01560 A IN2014MN01560 A IN 2014MN01560A IN 1560MUN2014 A IN1560MUN2014 A IN 1560MUN2014A IN 2014MN01560 A IN2014MN01560 A IN 2014MN01560A
Authority
IN
India
Prior art keywords
crystalline forms
quinazolin
difluorophenyl
triazol
chloro
Prior art date
Application number
Other languages
English (en)
Inventor
Antonio Canovas Paredes
Javier Bartroli Orpi
Elies Molins Grau
Anna Roig Serra
Kevin Meyer
Keith Lorimer
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39082545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01560(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06380225A external-priority patent/EP1887004A1/fr
Priority claimed from EP07380186A external-priority patent/EP2009009A1/fr
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of IN2014MN01560A publication Critical patent/IN2014MN01560A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1560MUN2014 2006-08-07 2007-08-06 IN2014MN01560A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83586306P 2006-08-07 2006-08-07
EP06380225A EP1887004A1 (fr) 2006-08-07 2006-08-07 Formes cristallines de (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one
US92940807P 2007-06-26 2007-06-26
EP07380186A EP2009009A1 (fr) 2007-06-26 2007-06-26 Composés antifongiques cristallins
PCT/US2007/017476 WO2008021049A2 (fr) 2006-08-07 2007-08-06 Composés cristallins antifongiques

Publications (1)

Publication Number Publication Date
IN2014MN01560A true IN2014MN01560A (fr) 2015-05-08

Family

ID=39082545

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1560MUN2014 IN2014MN01560A (fr) 2006-08-07 2007-08-06

Country Status (17)

Country Link
US (2) US7879867B2 (fr)
EP (2) EP2650291B1 (fr)
JP (3) JP2010513222A (fr)
KR (1) KR20090053903A (fr)
CN (1) CN103232442B (fr)
AR (1) AR062232A1 (fr)
AU (1) AU2007284851B2 (fr)
BR (1) BRPI0716026A2 (fr)
CA (1) CA2658843A1 (fr)
DK (1) DK2650291T3 (fr)
ES (1) ES2652670T3 (fr)
IL (2) IL196722A (fr)
IN (1) IN2014MN01560A (fr)
MX (1) MX2009001208A (fr)
RU (1) RU2500679C2 (fr)
TW (1) TWI426073B (fr)
WO (1) WO2008021049A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
EP2662374A1 (fr) * 2006-04-05 2013-11-13 OPKO Health, Inc. Sels d'hydrochlorure de 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one et leur procédé de préparation
ITMI20062449A1 (it) * 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
ES2548998T3 (es) * 2009-05-29 2015-10-22 Palau Pharma, S.A. Composiciones antifúngicas de azol
JP2012532886A (ja) * 2009-07-10 2012-12-20 エボルバ アクチェンゲゼルシャフト ジイン組成物
CN102573475B (zh) * 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
US9435692B2 (en) 2014-02-05 2016-09-06 Lam Research Corporation Calculating power input to an array of thermal control elements to achieve a two-dimensional temperature output
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
GB201410407D0 (en) * 2014-06-11 2014-07-23 Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med Treatment of chagas disease
EA025187B1 (ru) * 2015-04-17 2016-11-30 Тагир Аббасели оглы Сулейманов Производное дитиокарбамата 2-((4-(4-метилпиперазин-1-ил)фенил)амино)-2-оксоетил4-этилпиперазин-1-карбодитиоат, обладающее антифунгальной активностью
EP4452232A1 (fr) * 2021-12-22 2024-10-30 Palau Pharma, S.L.U. Composition d'albaconazole multiparticulaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293500A1 (fr) 1987-06-01 1988-12-07 American Cyanamid Company 3-Hétéroalkyl-2,4-quinazoline-diones, 3-hétéroaryl-1,2,3-benzotriazin-4(3H)-ones, 3-hétéroarylalkyl-4-quinazolinone
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
TW218017B (fr) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
TW297813B (fr) * 1993-09-24 1997-02-11 Takeda Pharm Industry Co Ltd
CA2134417A1 (fr) * 1993-12-22 1995-06-23 Katsumi Itoh Derives azotes optiquement actifs leur production et leur utilisation
KR100423590B1 (ko) * 1995-08-02 2004-09-10 호따. 우리아치에씨아. 에세. 아. 항진균활성을갖는신규피리미돈유도체
AU6119798A (en) * 1997-03-05 1998-09-22 Takeda Chemical Industries Ltd. Crystalline form of a bis 1,2,4-triazole compound
ES2159488B1 (es) 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.

Also Published As

Publication number Publication date
EP2049504A2 (fr) 2009-04-22
WO2008021049A9 (fr) 2008-10-30
US20080076787A1 (en) 2008-03-27
WO2008021049A2 (fr) 2008-02-21
AR062232A1 (es) 2008-10-22
EP2049504A4 (fr) 2010-09-22
IL196722A (en) 2016-10-31
EP2650291A1 (fr) 2013-10-16
JP2010513222A (ja) 2010-04-30
IL196722A0 (en) 2009-11-18
IL248216B (en) 2018-03-29
JP2014012673A (ja) 2014-01-23
DK2650291T3 (en) 2017-10-23
TWI426073B (zh) 2014-02-11
KR20090053903A (ko) 2009-05-28
AU2007284851A1 (en) 2008-02-21
TW200823197A (en) 2008-06-01
EP2650291B1 (fr) 2017-10-04
AU2007284851B2 (en) 2013-05-09
WO2008021049A3 (fr) 2008-12-31
MX2009001208A (es) 2009-04-14
RU2500679C2 (ru) 2013-12-10
RU2009104959A (ru) 2010-08-20
BRPI0716026A2 (pt) 2013-08-06
US8258296B2 (en) 2012-09-04
ES2652670T3 (es) 2018-02-05
CN103232442B (zh) 2015-01-21
CA2658843A1 (fr) 2008-02-21
CN103232442A (zh) 2013-08-07
US7879867B2 (en) 2011-02-01
US20110092702A1 (en) 2011-04-21
JP2015193642A (ja) 2015-11-05

Similar Documents

Publication Publication Date Title
IN2014MN01560A (fr)
ATE534632T1 (de) Thiazole, imidazole und pyrazole als proteinkinasehemmer
EP2476679A3 (fr) Triazoles substitués utilisés comme inhibiteurs AXL
EP2484679A3 (fr) Triazoles substitués par n3-hétéroaryle et N5-hétéroaryle triazoles substitués utiles comme inhibiteurs de axl
TW200736250A (en) Aminopyrimidines useful as kinase inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2008083367A3 (fr) Triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs de axl
MX2009006690A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2010038086A8 (fr) Nouveaux composés
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2010005876A3 (fr) Triazoles à substitution hétéroaryle polycycliques utiles en tant qu’inhibiteurs d’axl
WO2008137619A3 (fr) Thiazoles et pyrazoles qui s'utilisent comme inhibiteurs de kinase
WO2008147626A3 (fr) Thiazoles et pyrazoles utiles en tant qu'inhibiteurs de kinase
UA104731C2 (ru) Ингибиторы р38 мар-киназ
TW200714604A (en) Substituted heterocycles and the uses thereof
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
EP3037421A3 (fr) Inhibiteurs de mlk et procédés d'utilisation
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2007129226A3 (fr) Traitement de troubles cellulaires prolifératifs
WO2007059202A3 (fr) Derives de pyrazolyluree utilisables dans le traitement du cancer